EDGC Signs Joint Research and Commercialization Agreement on Liquid Biopsy with Gachon University
EDGC, a precision medicine company specializing in genomic analysis, announced on the 11th that it has signed a memorandum of understanding (MOU) for joint research and commercialization of liquid biopsy with Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute.
Attending the signing ceremony held at Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute were EDGC CEO Minseop Lee, Dr. Yeonju Hwang from the Genomic Research Center, and Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute Director Insang Yoo and Deputy Director Byungchul Oh.
They will conduct joint research to develop and commercialize liquid biopsy technology based on genomics and epigenomics for discovering cancer biomarkers. They also plan to collaborate on publishing papers related to liquid biopsy technology, securing national projects, research grants, and commercialization.
Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute will also participate in the consortium for developing the epigenetic biomarker discovery platform EpiCatch, which is planned by EDGC.
The EpiCatch consortium, led by EDGC, plans to conduct joint research with domestic and international hospitals and research facilities to discover epigenetic biomarkers. Through the consortium, epigenetic biomarker data will be standardized, and the standardized data will be analyzed more accurately and precisely by applying deep learning neural network AI algorithms. This initiative aims to lead to the commercialization of genomic analysis diagnostics and targeted therapeutic new drugs.
EDGC CEO Minseop Lee said, "We expect significant synergy in joint liquid biopsy research through the excellent facilities and research personnel capabilities of Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute," adding, "We plan to create meaningful research outcomes by advancing liquid biopsy technology based on epigenomics."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- [Seoul, Now] Redevelopment Speed Pledge No.1: Without On-Site Insight, It Becomes the First Failure
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Gachon University Lee Gil-yeo Cancer and Diabetes Research Institute was established on May 9, 2008, to conduct research on the diagnosis, treatment, and prevention of cancer and diabetes, coinciding with the 50th anniversary of Gachon University Gil Hospital and the 10th anniversary of the College of Medicine. The institute has built a nationally designated metabolic disease pharmacological efficacy evaluation center, providing specialized efficacy evaluation services for candidate substances to domestic and international pharmaceutical companies, and is striving to create an efficient research ecosystem.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
